Drug Profile
Research programme: peptide-based cancer therapeutics - ENKAM
Alternative Names: Dekafin2; EncaminC; Inherbin3; InherbinsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator ENKAM Pharmaceuticals A/S
- Class Peptides
- Mechanism of Action Epidermal growth factor receptor antagonists; Fibroblast growth factor receptor agonists; Protein tyrosine kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Denmark (Parenteral)
- 12 Nov 2007 Preclinical trials in Solid tumours in Denmark (Parenteral)